Retina

Study highlights extracellular matrix-related proteins expressed in PVR.

Clues to diagnosis from patient/family histories, examination techniques.

Trial shows treatment has acceptable safety profile, may improve visual function.

Knowledge of tools used in data interpretation helps clinicians trust accuracy of findings.

Novel treatments are now shifting paradigm in care of retinal diseases.

Retinal imaging tests are providing material to train and test decision-support systems.

If approved, PDS ranibizumab would become the first and only eye implant with continuous drug delivery offering people with wet AMD.

Increased access is key to preventing disease progression in patients.

Visible-light optical coherence tomography proves valuable in studies.

Investigators find approach improved vision and visual fields in some patients.

Clearside Biomedical, Inc. reported today positive safety results from Cohort 1 of its ongoing OASIS phase1/2a clinical trial of CLS-AX for the treatment of wet AMD.

RGX-314 eyed by investigators as a therapeutic option for exudative AMD.

Study results show that aflibercept-treated eyes are protected.

ADVM-022 offers sharp decrease in treatment burden for patients with nAMD.

The company is hoping to commercialize the first FDA-approved ophthalmic formulation of bevacizumab-vikg for retinal disease. It expects to receive BLA approval from the FDA by mid-2022.

Dexamethasone implant is key to treating non-infectious posterior segment uveitis.

Experts discuss durability of action and atrophy inhibitor among primary treatment goals.

A study led by investigators at St. Michael's Hospital of Unity Health Toronto supports pneumatic retinopexy as a primary retinal reattachment technique to achieve better long-term integrity of photoreceptors.

Option has a broader biologic effect for patients.

Worldwide increase in technologies for ophthalmic use is dramatic.

Michael A. Singer, MD, speaks on the highlights of his presentation focusing on IOP in the PALADIN 24-month data intravitreal steroid (ILUVIEN).

Studies on nurse-led services find a low level of complications among patients.

According to Applied Genetic Technologies Corp., groups 5 and 6 had a 50% response rate among patients who met the inclusion criteria for the Skyline and Vista trials.

Theodore Leng, MD, discusses the highlights from his presentation on "AAO IRIS Registry Data Replicates VIEW 1 and VIEW 2 Clinical Trial Outcome Data," during the virtual 2021 ARVO meeting.

Michael Mbagwu, MD, speaks on the highlights of his virtual 2021 ARVO presentation regarding the development of an algorithm tool that links patient imaging to their clinical data, specifically within the AAO IRIS Registry.

Daniel F. Kiernan, MD, discusses key findings of a clinical study analyzing the effect of dexamethasone intracameral drug-delivery suspension on macular thickness based on OCT testing following vitreoretinal surgery.

Glenn J. Jaffe, MD, discusses the key points of his virtual presentation on targeting neurodegenerative diseases with risuteganib, minimizing damage to the retina when compromised, and the need for newer treatment therapies to target different pathways.

Steffen E. Künzel, MD, discusses the key points of his research presentation regarding low vulnerability of the posterior eye segment to SARS-CoV-2 infection.

During ARVO 2021, Sunil Srivastava, MD, points out that optical coherence tomography characteristics may be predictive of the efficacy of the injections.